| DR. REDDY'S LABORATORIES LTD. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120130084 | PREPARATION OF FIPAMEZOLE - The application relates to processes for preparing fipamezole and its pharmaceutically acceptable salts, and intermediates thereof. It also provides intermediate compounds of Formula III and Formula IV, and processes for their preparation. | 05-24-2012 |
| 20120101297 | PRODUCTION OF TRANS-4-AMINOCYCLOPENT-2-ENE-1-CARBOXYLIC ACID DERIVATIVES - Methods of producing compositions of trans-4-amino-2-cyclopentene-1-carboxylic acid derivatives are described. Also described is an amine salt of a compound having formula A, | 04-26-2012 |
| 20120064161 | MODIFIED RELEASE NIACIN PHARMACEUTICAL FORMULATIONS - Pharmaceutical formulations comprising niacin in a matrix comprising a hydrophobic polymer that modifies release of niacin. | 03-15-2012 |
| 20120046457 | PREPARATION OF DECITABINE - The present application relates to processes for the preparation and purification of decitabine structurally represented by formula (I): | 02-23-2012 |
| 20120045505 | FIXED DOSE DRUG COMBINATION FORMULATIONS - Pharmaceutical formulations comprising multiple drugs, for treating or preventing cardiovascular disease. Embodiments are capsules containing individual drugs, or combinations of drugs, in the form of small tablets. | 02-23-2012 |
| 20120041043 | Sulfonamide Compounds for the Treatment of Respiratory Disorders - Compounds of formula (I) are agonists of PPARγ, useful for the treatment of respiratory disease; formula (I): wherein R | 02-16-2012 |
| 20110275841 | PREPARATION OF DOCETAXEL - The present invention relates to docetaxel and processes for preparing docetaxel, including process-related intermediates. The present invention also relates to processes for preparing substantially pure docetaxel and intermediates. | 11-10-2011 |
| 20110237802 | LENALIDOMIDE SOLVATES AND PROCESSES - The present application relates to lenalidomide salts and solvates, and processes for the preparation thereof. | 09-29-2011 |
| 20110236475 | GRANULAR PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions comprising a plurality of formulated particles containing at least one active ingredient and at least one pharmaceutically acceptable excipient, granulated with a granulating composition containing at least one pharmaceutical excipient. | 09-29-2011 |
| 20110224422 | PREPARATION OF CAPECITABINE - The present invention relates to substantially pure capecitabine and processes for the preparation thereof. | 09-15-2011 |
| 20110218360 | PREPARATION OF RASAGILINE AND SALTS THEREOF - The present invention relates to processes for the preparation of rasagiline mesylate. Also provided is rasagiline mesylate having 90 volume percent of the particles (D | 09-08-2011 |
| 20110213150 | PREPARATION OF CRYSTALLINE PALONOSETRON HYDROCHLORIDE - Processes for the preparation of palonosetron hydrochloride and its crystalline forms. | 09-01-2011 |
| 20110201800 | AZACITIDINE PROCESS AND POLYMORPHS - Processes for preparing azacitidine. Further included are processes for the preparation of crystalline azacitidine crystalline Form (I) and mixtures of azacitidine crystalline Forms (I) and (II). | 08-18-2011 |
| 20110201631 | PHARMACEUTICAL FORMULATIONS COMPRISING PEMETREXED - Pharmaceutical formulations comprising amorphous pemetrexed or its salts, and processes to prepare the formulations. | 08-18-2011 |
| 20110196154 | AMORPHOUS PEMETREXED DISODIUM - Processes for the preparation of amorphous pemetrexed disodium, and removal of residual solvents from amorphous pemetrexed disodium. | 08-11-2011 |
| 20110178470 | PHARMACEUTICAL COMPOSITIONS COMPRISING BORONIC ACID COMPOUNDS - Pharmaceutical compositions comprising bortezomib for oral or parenteral administration. Specific aspects relate to stable, sugar free pharmaceutical compositions of bortezomib, including its pharmaceutically acceptable salts or solvates, in the form of ready-to-use solutions, lyophilized forms, or physical admixtures, and the preparation thereof. Other aspects include processes for preparing compositions and methods of using compositions for treating various types of cancers in mammals. | 07-21-2011 |
| 20110159084 | RALOXIFENE PHARMACEUTICAL FORMULATIONS - Pharmaceutical formulations comprising raloxifene or its salts, esters, polymorphs, isomers, hydrates, solvates, or derivatives thereof having defined particle sizes. Also described are processes for preparing formulations and methods of using such formulations. | 06-30-2011 |
| 20110151258 | PREPARATION OF RANOLAZINE - Preparation of ranolazine and intermediates thereof, for use in pharmaceutical compositions comprising ranolazine. | 06-23-2011 |
| 20110123575 | MODIFIED RELEASE NIACIN FORMULATIONS - Modified release pharmaceutical formulations comprising niacin in a non-swellable core, and processes for preparation of the formulations. | 05-26-2011 |
| 20110098452 | PURIFICATION OF MODIFIED CYTOKINES - The invention provides an efficient method of purification of a modified cytokine. The process includes the use of a chromatographic technique for the purification of the desired cytokine. The purified cytokine can be used as a therapeutic composition. | 04-28-2011 |
| 20110086074 | COMBINATIONS OF NIACIN AND AN OXICAM - Pharmaceutical formulations comprising a combination of niacin and an oxicam NSAID, for oral administration, and methods of preparing the formulations. | 04-14-2011 |
| 20110064816 | ATORVASTATIN COMPOSITIONS - Compositions containing atorvastatin, including its pharmaceutically acceptable salts, solvates, hydrates, enantiomers, polymorphs and their mixtures, and processes for preparing the same. Further aspects relate to pharmaceutical formulations comprising compositions containing atorvastatin, or a salt thereof, processes for preparing the same, and their methods of use, treatment and administration. | 03-17-2011 |
| 20110040095 | PREPARATION OF MONTELUKAST AND ITS SALTS - Processes for preparing montelukast acid and its salts. | 02-17-2011 |
| 20110028518 | DEXLANSOPRAZOLE PROCESS AND POLYMORPHS - Processes for the preparation of dexlansoprazole, an amorphous form of dexlansoprazole, a solid dispersion of amorphous dexlansoprazole and a pharmaceutically acceptable carrier, and processes for their preparation. Also provided are crystalline compounds 2-[(R)-[(4-chloro-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole and 2-[(R)-[(4-nitro-3-methyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, and methods for their preparation. | 02-03-2011 |
| 20110021567 | PREPARATION OF LENALIDOMIDE - Processes for the preparation of substantially pure lenalidomide. The application also relates to an enriched, substantially pure, and pure amorphous form of lenalidomide and solid dispersions containing amorphous lenalidomide. | 01-27-2011 |
| 20110009362 | SOLUBILITY-ENHANCED FORMS OF APREPITANT AND PHARMACEUTICAL COMPOSITIONS THEREOF - Solubility-enhanced forms of aprepitant and processes for preparing such forms. The invention also provides solubility-enhanced forms of aprepitant that also possess stability against solid state conversions. Certain solubility-enhanced forms of aprepitant comprise a cyclodextrin or any of its derivatives. Other solubility-enhanced forms of aprepitant comprise fine particle preparations of aprepitant. The invention further provides non-nanoparticulate pharmaceutical formulations prepared using solubility-enhanced forms of aprepitant. The invention also provides taste-masked and orally disintegrating pharmaceutical formulations comprising aprepitant. Further, pharmaceutical formulations comprising solubilityenhanced forms of aprepitant and processes of preparation of such formulations, as well as methods of using them are provided. | 01-13-2011 |
| 20100298327 | APREPITANT POLYMORPH MIXTURES - Intimate mixtures of aprepitant crystalline Form I and crystalline Form II, having specific Hweight ratios of the forms. | 11-25-2010 |
| 20100274017 | PROCESSES FOR THE PREPARATION OF SITAGLIPTIN AND PHARMACEUTICLLY ACCEPTABLE SALTS THEREOF - There is provided salts and polymorphs of sitagliptin, processes for the preparation thereof, and pharmaceutical compositions comprising the same. | 10-28-2010 |
| 20100261908 | PROCESSES FOR THE PREPARATION OF PRASUGREL , AND ITS SALTS AND POLYMORPHS - Processes for the preparation of prasugrel and its pharmaceutically acceptable salts thereof. Also disclosed are polymorphic forms of prasugrel hydrochloride and processes for their preparation. | 10-14-2010 |
| 20100247649 | PHARMACEUTICAL FORMULATIONS COMPRISING TELMISARTAN AND HYDROCHLOROTHIAZIDE - Pharmaceutical tablets comprising a first layer formulated for immediate release of telmisartan from a dissolving matrix and a second layer formulated for immediate release of hydrochlorothiazide from a dissolving matrix, methods for producing tablets and methods of use for treating hypertension. | 09-30-2010 |
| 20100210719 | O-DESMETHYLVENLAFAXINE - Processes for preparing desvenlafaxine and stable amorphous O-desmethylvenlafaxine succinate solid dispersions with one or more pharmaceutically acceptable carriers. | 08-19-2010 |
| 20100174085 | CRYSTALLINE POLYMORPHIC FORMS OF FEXOFENADINE - The present invention is related to a novel polymorph of Fexofenadine and processes of preparation thereof. | 07-08-2010 |
| 20100160653 | DOCETAXEL POLYMORPHS AND PROCESSES - The present invention provides crystalline polymorphs of docetaxel and processes for preparing them, a method for preparing amorphous docetaxel, and a process for preparing docetaxel. | 06-24-2010 |
| 20100144731 | Novel Biccyclic Compounds As GATA Modulators - Novel bicyclic compounds, stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided. Additionally, methods of forming novel bicyclic compounds, stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided. | 06-10-2010 |
| 20100144722 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS - Novel heterocyclic compounds, sstereoisomers thereof and/or pharmaceutically acceptable salts of formula (I) and its stereoisomers are provided. Additionally, methods of forming novel heterocyclic compounds, stereoisomers thereof and/or pharmaceutically acceptable salts of formula (I) and its stereoisomers are provided. | 06-10-2010 |
| 20100137358 | SOLIFENACIN COMPOSITIONS - Compositions and/or formulations comprising solifenacin or a salt thereof and processes for preparing the same. Certain compositions and formulations contain a stable amorphous form of solifenacin succinate. | 06-03-2010 |
| 20100130734 | PROCESS FOR PREPARING CAPECITABINE - There is provided processes for the preparation of capecitabine and intermediates thereof. | 05-27-2010 |
| 20100125149 | IBANDRONATE SODIUM POLYMORPHS - There are provided crystalline forms of Ibandronate sodium and process for preparing thereof. | 05-20-2010 |
| 20100087444 | IMATINIB MESYLATE - There is provided a solid dispersion of imatinib mesylate that includes imatinib mesylate and a pharmaceutically acceptable carrier, wherein said carrier is a cellulose derivative. Also provided is a process for making a solid dispersion and a process for making imatinib. | 04-08-2010 |
| 20100069635 | ROSUVASTATIN DEHYDROABIETYLAMINE SALT - There is provided a compound, which is dehydroabietylamine salt of rosuvastatin. Also provided are processes for making rosuvastatin calcium that include formation of dehydroabietylamine salt of rosuvastatin. | 03-18-2010 |
| 20100063083 | 5(S)-(2'-HYDROXYETHOXY)-20(S)-CAMPTOTHECIN AND ITS PREPARATION AND USE FOR THE TREATMENT OF CANCER - A 5(S)-(2′-hydroxyethoxy)-20(S)-camptothecin diasterisomer is described which is a better inhibitor of topoisomerase I than either the diastereoisomeric mixture 5(RS)-(2′-hydroxyethoxy)-20(S)-camptothecin, or the 5(R)-(2′-hydroxyethoxy)-20(S)-camptothecin diastereoisomer. Pharmaceutical compositions of the 5(S)-(2′-hydroxyethoxy)-20(S)-camptothecin diastereoisomer are also described as are methods of using the compound for the inhibition of topoisomerase I and for the treatment of cancer. | 03-11-2010 |
| 20100063072 | SOLID FORMS OF PEMETREXED - Duplex coating schemes and associated methods of formation, including a siloxane-based soft coating and a plasma-based SiO | 03-11-2010 |
| 20100029743 | ATORVASTATIN PHARMACEUTICAL COMPOSITIONS - The present invention relates to pharmaceutical formulations of atorvastatin or its pharmaceutically acceptable salts, solvates, hydrates, enantiomers, polymorphs or their mixtures; and processes for preparing the same, and their methods of use, treatment and administration. Further, the present invention relates to pharmaceutical compositions comprising an acid-solubility-enhanced form of atorvastatin or its salts. | 02-04-2010 |
| 20090326230 | PROCESS FOR PREPARING SOLIFENACIN AND ITS SALTS - The present invention relates to solifenacin in solid form and a process for its preparation and to a process for the preparation of (1S)-1-Phenyl-1,2,3,4-tetrahydro-isoquinoline, a key intermediate in the synthesis of solifenacin and its salts. | 12-31-2009 |
| 20090252787 | GRANULAR PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions comprising a plurality of formulated particles containing at least one active ingredient and at least one pharmaceutically acceptable excipient, granulated with a granulating composition containing at least one pharmaceutical excipient. | 10-08-2009 |
| 20090247529 | TOPICAL COMPOSITIONS - Single phase pharmaceutical compositions for topical application, in addition to kits and methods of use and administration are provided. The compositions comprise a biologically active agent; a delivery vehicle comprising at least a non-polymeric crystallization inhibitor and a film-former; and a volatile solvent; wherein the biologically active agent is present in the composition in a subsaturated state, the biologically active agent is present in the delivery vehicle in a supersaturated state, and the crystallization inhibitor is capable of delaying crystallization of the biologically active agent in the delivery vehicle. Biologically active agents include terbinafine and acyclovir. Treatments for onychomycosis and Varicella zoster infection, HSV-1 infection or HSV-2 infection are provided. | 10-01-2009 |
| 20090209541 | APREPITANT COMPOSITIONS - Pharmaceutical compositions comprising aprepitant, wherein aprepitant solubility in aqueous media is enhanced. | 08-20-2009 |
| 20090111776 | Novel tetracycline derivatives as antibacterial agents - In accordance with one aspect, the present invention provides a compound of general formula (I), its stereoisomers thereof and/or its pharmaceutically acceptable salts thereof, which have antibacterial activity; with methods of treating infectious diseases in warm blooded animals employing these new compounds. | 04-30-2009 |
| 20090069557 | PREPARATION OF GEMCITABINE - A process for preparation of gemcitabine hydrochloride and purification thereof. | 03-12-2009 |
| 20090054455 | ARIPIPRAZOLE CO-CRYSTALS - Co-crystals comprising aripiprazole and fumaric acid. | 02-26-2009 |
| 20090018351 | PREPARATION OF ESCITALOPRAM - The present invention relates to a process for preparing enantiomerically enriched citalopram via methylating enantiomerically enriched didesmethylcitalopram, which is prepared by directly resolving racemic didesmethylcitalopram using a chiral acid. | 01-15-2009 |
| 20080214823 | Preparation of Montelukast - A process for preparing amorphous montelukast sodium comprises removing solvent from a solution comprising montelukast sodium using agitated thin film drying. | 09-04-2008 |
| 20080214535 | Amorphous Aprepitant Coprecipitates - A coprecipitate comprising amorphous aprepitant and a pharmaceutically acceptable carrier is prepared by rapidly removing solvent from a solution containing aprepitant and the carrier. | 09-04-2008 |
